The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference

Matthew Masoli, Joseph W. Lanario, Michael E. Hyland, Andrew Menzies-Gow, Adel H. Mansur, David Allen, James W. Dodd, Gemma Hayes, Jose M. Valderas, Sarah E. Lamb, Rupert C. Jones

Research output: Contribution to journalArticle (Academic Journal)peer-review

Original languageEnglish
Article number2100300
JournalEuropean Respiratory Journal
Volume57
Issue number6
DOIs
Publication statusPublished - 25 Jun 2021

Bibliographical note

Funding Information:
from the Research Ethics Committee/Health Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was sponsored by University Hospitals Plymouth NHS Trust.

Funding Information:
during the conduct of the study. J.W. Lanario reports grants from GSK, during the conduct of the study; personal fees from Novartis, outside the submitted work. M.E. Hyland reports grants from GSK, during the conduct of the study; personal fees from GSK, outside the submitted work. A. Menzies-Gow reports grants and personal fees from AstraZeneca, personal fees and non-financial support from Teva, and personal fees from Novartis, GlaxoSmithKline, Sanofi, Roche and Vectura, outside the submitted work. A.H. Mansur reports grants, personal fees, non-financial support and other (for various activities that include talks, advisory board meeting, sponsorship for conferences) from NAPP, Cheisi, AstraZeneca, GSK, Sanofi, Teva, outside the submitted work. D. Allen reports personal fees (advisory boards) from AstraZeneca and GSK, personal fees and non-financial support from Teva (speaker fees, and sponsorship support to attend conferences), outside the submitted work. J.W. Dodd has nothing to disclose. G. Hayes has nothing to disclose. J.M. Valderas has nothing to disclose. S.E Lamb was on the Health Technology Assessment (HTA) Additional Capacity Funding Board, HTA End of Life Care and Add-on Studies Board, HTA Prioritisation Group Board and the HTA Trauma Board. R.C. Jones reports grants from GlaxoSmithKline, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca and GlaxoSmithKline, personal fees and non-financial support from Boehringer Ingelheim, Novartis, Nutricia and OPRI, outside the submitted work.

Cite this